Results 11 to 20 of about 12,875 (250)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure

Biology, 2023
Acute-on-chronic liver failure (ACLF) has a high risk of short-term mortality. A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF)
Hiroaki Takaya, Tadashi Namisaki, Masahide Enomoto, Takahiro Kubo, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Kosuke Kaji, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji   +12 more
doaj   +2 more sources

Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients.

PLoS ONE, 2021
Sepsis is a life-threatening disease characterized by excessive host response to infection that can lead to activation of the coagulation system. Von Willebrand Factor (VWF) and ADAMTS13 are important regulators of hemostasis and their dysregulation ...
Kanwal Singh, Andrew C Kwong, Hasam Madarati, Sharumathy Kunasekaran, Taylor Sparring, Alison E Fox-Robichaud, Patricia C Liaw, Colin A Kretz   +7 more
doaj   +2 more sources

Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients

TH Open, 2021
The causes of coagulopathy associated with coronavirus disease 2019 (COVID-19) are poorly understood. We aimed to investigate the relationship between von Willebrand factor (VWF) biomarkers, intravascular hemolysis, coagulation, and organ damage in COVID-
Joseph M. Sweeney, Mohammad Barouqa, Gregory J. Krause, Jesus D. Gonzalez-Lugo, Shafia Rahman, Morayma Reyes Gil   +5 more
doaj   +2 more sources

Molecular Biology of ADAMTS13 and Diagnostic Utility of ADAMTS13 Proteolytic Activity and Inhibitor Assays [PDF]

Seminars in Thrombosis and Hemostasis, 2005
ADAMTS13, a reprolysin-like metalloprotease, limits platelet-rich thrombus formation in the small arteries by cleaving von Willebrand factor (vWF) at the Tyr1605-Met1606 peptide bond. Deficiency of plasma ADAMTS13 activity, due to either an inherited or an acquired etiology, may lead to a potentially lethal syndrome, thrombotic thrombocytopenic purpura
Suresh G. Shelat, X. Long Zheng, Jihui Ai   +2 more
openaire   +4 more sources

Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels [PDF]

Blood Advances, 2017
Key Points Three independent association signals at ADAMTS13 and smoking were identified as major predictors of plasma ADAMTS13 levels. Evidence was presented that 2 nonsynonymous ADAMTS13 variants were driving the variation of plasma ADAMTS13 concentrations.
Chava Kimchi-Sarfaty, Colin A. Kretz, David Ginsburg, Jun Li, Beth McGee, Paula M. Jacobi, Qianyi Ma, Ayse Bilge Ozel, Karl C. Desch, Brian T. Emmer   +9 more
openaire   +5 more sources

ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study

Thrombosis Journal, 2021
Background We conducted a prospective observational study for investigating the changes in the 13th member of a disintegrin-like and metalloprotease with thrombospondin type 1 motif (ADAMTS13) and its association with the coagulofibrinolytic response in ...
Hironori Matsumoto, Jun Takeba, Kensuke Umakoshi, Satoshi Kikuchi, Muneaki Ohshita, Suguru Annen, Naoki Moriyama, Yuki Nakabayashi, Norio Sato, Mayuki Aibiki   +9 more
doaj   +2 more sources

A Thrombocytopenic Thrombotic Purpura in a Patient With a Metastatic HER2+ Breast Cancer: Description of a Case Report [PDF]

Clinical Case Reports, Volume 13, Issue 4, April 2025.
ABSTRACT Paraneoplastic (p) TTP is a rare syndrome characterized by an immune‐induced, generalized microangiopathy associated with solid or hematological tumors. This case, reporting a patient with a metastatic HER2+ breast cancer and a pTTP, highlights the rarity of this entity, its difficult and challenging diagnosis, and the complexity of its ...
Raffaele Longo, Benjamin Savenkoff, Romane Ribal, Alexandre Dadoun, Marco Campitiello, Francesca Plastino, Pierre‐Olivier Legros, Nathalie Marcon, Paul Coppo, Julie Egea   +9 more
wiley   +2 more sources

Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura [PDF]

Antibodies
Autoantibodies to ADAMTS13 are at the center of pathology of the immune-mediated thrombotic thrombocytopenic purpura. These autoantibodies can be either inhibitory (enzymatic function) or non-inhibitory, resulting in protein depletion.
Michael R. Snyder, Robert W. Maitta
doaj   +2 more sources

Systemic antithrombotic effects of ADAMTS13 [PDF]

The Journal of Experimental Medicine, 2006
The metalloprotease ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats 13) cleaves highly adhesive large von Willebrand factor (VWF) multimers after their release from the endothelium. ADAMTS13 deficiency is linked to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized by platelet-rich ...
David G. Motto, Barbara Plaimauer, Friedrich Scheiflinger, David Ginsburg, Colin B. Lamb, Denisa D. Wagner, Anil K. Chauhan, Michael Dockal, Wolfgang Bergmeier   +8 more
openaire   +5 more sources

Efficacy and Safety of Rituximab in Connective Tissue Disease‐Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy [PDF]

International Journal of Rheumatic Diseases, Volume 28, Issue 6, June 2025.
ABSTRACT Introduction This study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)‐associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.
Naoaki Ohkubo, Shingo Nakayamada, Shunsuke Fukuyo, Yusuke Miyazaki, Yoshino Inoue, Hiroaki Tanaka, Yasuyuki Todoroki, Yoshiya Tanaka   +7 more
wiley   +2 more sources